OneVentures, a venture fund based in Sydney, Australia, was founded in 2006. Specializing in Seed to Series D investments, the fund focuses on BioTech, Medical Device, and Pharmaceuticals sectors. With a portfolio including Axial Biotherapeutics, OneVentures has made 52 investments and has had 3 exits. Anne-Marie Birkill is a key partner at the firm, reachable at abirkill@one-ventures.com. OneVentures prides itself on investing in groundbreaking technology and healthcare companies, positioning itself as a leader in the Australian venture capital scene.